Pfizer Stocks (PFE) continue to be a topic of numerous analyses, with varied expectations for its future performance. While there are forecasts suggesting a bleak financial future, other readings imply growth potential from pipeline execution. The stocks have caught the attention of numerous buyers, as evidenced by recent purchases by Adams Asset Advisors LLC, Wilsey Asset Management Inc., and Czech National Bank among others. However, Pfizer's weak 2026 outlook, on the back of fading COVID sales and mounting margin pressures, resulted in a drop in the stock price. Furthermore, Pfizer is believed to be facing challenges in compensating for its shrinkage in COVID revenue. Predictions include a steady rating for Pfizer amidst a neutral market outlook and pipeline progress. Analysts at Guggenheim and BMO appear bullish with price targets set at $35 and $30, respectively. Among concerns are price target reductions from BofA and Wolfe Research due to increased erosion of Pfizer’s COVID products. The stock remained steady after hours following some recent developments, with anticipation high ahead of future guidance announcements.
Pfizer Stocks News Analytics from Tue, 30 Sep 2025 07:00:00 GMT to Sat, 20 Dec 2025 23:56:40 GMT -
Rating -4
- Innovation -1
- Information 6
- Rumor 2
